1. Plunkett, L.M., Becker, R.A., Kaplan, M. An enhanced tiered toxicity testing framework with triggers for assessing hazards and risks of commodity chemicals. Regul. Toxicol. Pharmacol. 2010. Accepted for publication August.

2. Krewski, D., Chambers, A., Stern, B.A., Aggett, P.A., Plunkett, L., Rudenko, L. Development of a copper database for exposure-response analysis. J. Toxicol. Environ. Health. 2010. 73:208-216.

3. Plunkett, L.M., Becker, R.A. Does the standard toxicological testing paradigm for industrial chemicals apply to screening for children’s health risks? The Open Toxicol. J. 2008, 2:42-60.

4. Becker, R.A., Plunkett, L.M., Borzelleca, J.F., Kaplan, A.M. Tiered toxicity testing: Evaluation of toxicity-based decision triggers for human health hazard characterization. Food Chem. Toxicol. 2007, 45:2454-2469.

5. MacGregor, JA, Plunkett, LM, Youngren, SH, Manley, A, Plunkett, JB, Starr, TB. Humans Appear No More Sensitive than Laboratory Animals to the Inhibition of Red Blood Cell Cholinesterase by Dichlorvos (DDVP). Regul. Toxicol. Pharmacol., 2005, 43:150-167.

6. Plunkett, LM. Do current FIFRA guideline tests protect infants and children? Lead as a case study. J Regul Toxicol Pharmacol 1999;29:80-87.

7. Plunkett, LM, Seifen E, Kennedy RH. Effect of morphine pretreatment on cocaine cardiotoxicity in anesthetized guinea pigs. Arch Int Pharmacodyn 1989;297:60-67.

8. Zorbas M., Owens SM, Plunkett LM, Bui H. The pharmacokinetics of [3H]-[1-(2-thienyl)cyclohexyl]piperidine (TCP) in Sprague Dawley rats. J Drug Metab Disposit 1989;17:641-645.

9. Seifen E, Plunkett LM, Kennedy RH. Cardiovascular and lethal effects of cocaine in anesthetized dogs and guinea pigs. Arch Int Pharmacodyn 1989;300:241-253.

10. McCarty R., Plunkett LM. Regulation of binding sites for atrial natriuretic factor (ANF) in rat brain. Peptides 1988;9(S1):3-8.

11. Stewart RE, Swithers SE, Plunkett LM, McCarty R. ANF receptors: distribution and regulation in central and peripheral tissues. Neurosci Biobehav Rev 1988;12:151-168.

12. Plunkett LM, Tackett RL. Central dopamine receptors and their role in digoxin-induced cardiotoxicity in the dog. J Pharm Pharmacol 1987;39:29-34.

13. Plunkett LM, Tackett RL. Increases in CSF norepinephrine associated with the onset of cardiac glycoside toxicity. Eur J Pharmacol 1987;136:119-122.

14. McCarty R., Plunkett LM. Quantitative autoradiographic analysis of somatostatin binding sites in discrete areas of rat brain. Brain Res Bull 1987;18:289-94.

15. Plunkett LM, Shigematsu K, Kurihara M, Saavedra JM. Localization of angiotensin II receptors along the anteroventral-third ventricle area of the rat brain. Brain Res 1987;405:205-212.

16. Israel A, Plunkett LM, Saavedra JM. Increased number of angiotensin II binding sites determined by autoradiography in anterior pituitary of water deprived and Brattleboro rats. Neuroendocrinol 1986;42:57-63.

17. Saavedra JM, Correa FMA, Plunkett LM, Israel A, Kurihara M, Shigematsu K. Angiotensin and atrial natriuretic peptide binding in brain of hypertensive rats. Nature 1986;320:758-760.

18. McCarty RM, Plunkett LM. Forebrain atriopeptin binding sites: Alterations in spontaneously hypertensive rats. Neurochem Int 1986;9:177-183.

19. Shigematsu K, Saavedra JM, Plunkett LM, Kurihara M, Correa FMA. Angiotensin II binding sites in the anteroventral-third-ventricle (AV3V) area and related structures of the rat brain. Neurosci Lett 1986 67:37-41.　

20. Correa FMA, Plunkett LM, Saavedra JM. Quantitative distribution of angiotensin-converting enzyme (kininase II) in discrete areas of the rat brain by autoradiography with computerized microdensitometry. Brain Res 1986;275:259-266.

21. Saavedra JM, Israel A, Plunkett LM, Kurihara M, Shigematsu K, Correa FMA. Quantitative distribution of angiotensin II binding sites in rat brain by autoradiography. Peptides 1986;7:679-687.

22. McCarty R, Plunkett LM. Binding sites for atrial natriuretic factor (ANF) in brain: alterations in Brattleboro rats. Brain Res Bull 1986;17:767-772.

23. Plunkett LM, Gokhale RD, Vallner JJ, Tackett RL. Prazosin alters free and total plasma digoxin in dogs. Am Heart J 1985;109:847-851.

24. Plunkett LM, Tackett RL. The effects of central beta-receptor antagonism on digoxin cardiotoxicity. Res Comm Chem Path Pharmacol 1985;48:209-220.

25. Israel A, Saavedra JM, Plunkett L. Water deprivation upregulates angiotensin II receptors in rat anterior pituitary. Am J Physiol 1985;248 (Endocrino. Metabl. II):E264-E267.

26. Niwa M, Shigematsu K, Plunkett L, Saavedra JM. High affinity substance P binding sites in rat sympathetic ganglia. Am J Physiol 1985;249 (Heart Circ. Physiol 18):H694-H697.

27. Correa FMA, Plunkett LM, Saavedra JM, Hichens M. Quantitative autoradiographic determination of angiotensin-converting enzyme (kininase II) kinetics in individual rat brain nuclei with 125I-351A, a specific enzyme inhibitor. Brain Res 1985;347:192-195.

28. Israel A, Niwa M, Plunkett LM, Saavedra JM. High affinity angiotensin receptors in rat adrenal medulla. Regul Pept 1985;11:237-243.

29. Israel A, Plunkett LM, Saavedra JM. Quantitative autoradiographic characterization of receptors for angiotensin II and other neuropeptides in individual brain nuclei and peripheral tissues from single rats. Cell Mol Neurobiol 1985;5:211-222.

30. Plunkett LM, Correa FMA, Saavedra JM. Quantitative autoradiographic determination of angiotensin-converting enzyme kinetics in rat pituitary and adrenal glands with 125I-135A, a specific inhibitor. Regul Pept 1985;12:1-10.

31. Plunkett LM, Saavedra JM. Increased angiotensin II binding affinity in the nucleus tractus solitarius of spontaneously hypertensive rats. Proc Natl Acad Sci 1985;82:7721-7724.　

32. Plunkett LM, Tackett RL. Central alpha receptors and their role in digoxin cardiotoxicity. J Pharmacol Exp Ther 1983;227:683-686.

1. Plunkett, L.M., Starr, T.B., MacGregor, J.A., Manley, A. Corn oil as a causative factor for proliferative lesions of the forestaomach in B6C3F1 mice exposed by gavage. Society of Toxicology, Washington, D.C., to be presented March 2011.

2. Plunkett, L.M., MacGregor, J.A., Starr, T.B., Manley, A. Daily gavage with corn oil is a causative factor for proliferative lesions of the forestaomach in B6C3F1 mice. Toxicology Lett. 189S:S142. Presented at EUROTOX, Dresden, Germany, September 14, 2009.

3. Plunkett, L.M., MacGregor, J.A., Starr, T.B., Youngren, S.H., Manley, A. Determination of a dichlorvos-specific acute interspecies uncertainty factor. Society of Toxicology, Seattle, WA, March 19, 2008.

4. Plunkett, L.M., Starr, T.B., Youngren, S.H., MacGregor, J.A., Manley, A. Determination of the magnitude of intraspecies differences in red blood cell cholinesterase inhibition in response to dichlorvos exposure. Society of Toxicology, San Diego, CA, March 6, 2006.

5. Plunkett, L.M., Licata, J.M. What every technology manager needs to know about FDA law. Association of University Technology Managers (AUTM), Orlando, FL, March 4, 2006.

6. Plunkett, Licata JM What every technology manager needs to know about FDA law. Association of University Technology Managers (AUTM), Phoenix, AZ February 2005.

7. Plunkett LM. Qualitative Interpretation of Complex and Disparate Data Sets for Dose-Response Assessment of Essential Trace Elements: Copper as a Case Study. Society for Toxicology, Baltimore, MD March 2004 .

8. Plunkett LM. Evaluating qualitative and quantitative dose-response data in complete data sets for comparative dose-response assessment. Soc. Risk Analysis, Baltimore, MD, December 10, 2003.

9. Plunkett LM, Rieth S, Starr T. Issues in assessing risks for cholinesterase-inhibiting pesticides: A decision tree approach. Soc. Risk Analysis, New Orleans, LA, December 9-12, 1996

10. Plunkett LM, Brown S. Assessment of the potential neuropathic risk to banana workers from dermal exposure to chlorpyrifos. Soc. Risk Analysis, Honolulu, HI, December 3-7, 1995

11. Plunkett LM, Russell K. Cooperation versus Confrontation: Reconciling Lead regulations, exposure studies, and public perception. SEGH Conference, July, Salt Lake City, UT, 1994

12. Plunkett LM, Wixtrom RN, Cabrera CR. Evaluation of the long-term safety of inflatable penile prostheses: a critical analysis of potential carcinogenic, reproductive, teratogenic, or adverse immunological effects of silicone. Western Section of American Urological Association Meeting, Seattle, WA, August 21-25, 1994

13. Wixtrom RN, Plunkett LM, Clarkin CM. Complications of inflatable penile prostheses: A comprehensive review of infection, mechanical complications, erosion/migration/extrusion, and fibrous capsule formation. 1994.

14. Wixtrom RN, Clarkin CM, Purkait B, Plunkett LM. A review of clinical experience with the Mentor Alpha I and Mark II inflatable penile prostheses. 1994.

15. Plunkett LM, Rosolowsky LJ, Lerner DM, Washburn ST. A biokinetic model for predicting blood lead levels in adults living near a former battery recycling facility. SEGH Conference, New Orleans, LA, July, 1993.

16. Rosolowsky LJ, Edelmann KG, Plunkett LM. A biokinetic model for predicting blood lead levels in adults that accounts for intermittent exposures. Society for Risk Analysis, December, 1993

17. Plunkett LM, Owens SM , Gunnell M, Owens RB. The effect of chronic phencyclidine (PCP) and phenylcyclohexene (PC) dosing on [3H]TCP and [3H] haloperidol binding in rat brain. FASEB J 1990;4:A329.

18. Owens RB, Owens SM, Gunnell M, Plunkett LM. 1990. The effect of chronic phencyclidine (PCP) and phenylcyclohexene (PC) on lymphocyte in subsets in rats. FASEB J 1990;4:A337.

19. Zorbas M, Owens SM, Plunkett LM, Bui H. [3H]TCP protein binding and pharmacokinetics in Sprague-Dawley rat. FASEB J 1989;3:A1036.

20. Plunkett LM, Kennedy RH, Seifen E. Effects of chronic stress on myocardial beta-adrenergic receptor binding. The Pharmacologist 1988;A1300.

21. Evans, R.E., Plunkett LM, Kennedy RH, Seifen E. [3H]Ouabain binding to regions of rat heart as determined by autoradiography. The Pharmacologist 1988;A41.

22. Massey BW, Plunkett LM, Kennedy RH, Seifen E. Alterations in brain angiotensin II binding in the aged rat. Soc. Neuroscience 1987 Abstracts, p. 722.

23. Plunkett LM, Alexander N, Saavedra JM. Altered angiotensin II binding in adrenal gland, pituitary gland and brain of sinoaortic denervated rats. Am. Soc. Hypertension. New York, NY, May 1986.

24. Saavedra JM, Plunkett LM, Correa FMA. Increased number of angiotensin II binding sites in the subfornical organ of spontaneously hypertensive rates. Am. Soc. Hypertension, New York, NY, May 1986.

25. Plunkett LM, Niwa M, Shigematsu K, Saavedra JM. Increased angiotensin II (ANG) binding in superior cervical ganglia of spontaneously hypertensive rats (SHR). Fed. Proc 1985;3: 498.

26. Plunkett LM, Saavedra JM. Discrete localization of angiotensin II (ANG) binding sites in rat brainstem by quantitative autoradiography. Neural and Endocrine Peptides and Receptors, Symposium, Washington, D.C., May, 1985.

27. Plunkett LM, Israel A, Niwa M, Shigematsu K, Saavedra JM. Alterations in angiotensin II binding in pituitary gland, adrenal gland and superior cervical ganglia of spontaneously hypertensive rats (SHR) as determined by quantitative autoradiography. Neural and Endocrine Peptides and Receptors, Symposium, Washington, DC, May 1985.

28. Shigematsu K, Niwa M, Plunkett LM, Saavedra JM. High affinity substance P binding sites in rat sympathetic ganglia. Neural and Endocrine Peptide and Receptors, Symposium '85, Washington, DC, May 1985.

29. McCarty R, Plunkett LM, Israel A, Saavedra JM. Quantitation of somatostatin binding sites in rat brain. Neural and Endocrine Peptides and Receptors, Symposium '85, Washington, DC, May, 1985.

30. Plunkett LM, Saavedra JM. Increased angiotensin II (ANG) binding in brainstem nuclei of adult spontaneously hypertensive rats (SHR) by quantitative autoradiography. Interamerican Society of Hypertension, Cleveland, OH, May 1985.

31. Saavedra JM, Plunkett LM, Niwa M, Israel A, Shigematsu K, R. McCarty, Correa FMA. Autoradiographic-microdensitometric methods for the kinetic analysis of neuropeptide receptors and peptidases in individual brain nuclei. IVth World Congress of Biological Psychiatry, Philadelphia, PA, September, 1985.

32. Plunkett LM Saavedra JM. 1985. Altered angiotensin II binding in ganglia and brainstem nuclei of spontaneously hypertensive rats (SHR). Council for High Blood Pressure Research, Cleveland, OH, September 1985.

33. Plunkett LM, Correa FMA, Saavedra JM. Quantification of angiotensin-1-converting enzyme kinetics in individual rat pituitary and adrenal glands with 125I-MK351A, a specific enzyme inhibitor. Society for Neuroscience, Dallas, Texas, October 1985.

34. McCarty R, Plunkett LM, Shigematsu K, Saavedra JM. Quantitative autoradiographic analysis of somatostatin binding sites in discrete areas of rat brain. Society for Neuroscience, Dallas, Texas, October, 1985.

35. Correa FMA, Plunkett LM, Saavedra JM. Quantitative autoradiographic determination of angiotensin-converting enzyme distribution in rat brain with 125I-MK351A, a specific inhibitor. Society for Neuroscience, Dallas, Texas, October 1985.

36. Plunkett LM, Saavedra JM. Altered angiotensin II binding kinetics in brainstem, pituitary gland, and adrenal gland in adult SHR. 5th International Symposium on SHR and Related Studies, Tokyo, Japan, October, 1985.

37. Plunkett LM, Tackett RL. CSF catecholamine activity decreases during cardiac glycoside-induced arrhythmogenesis. The Pharmacologist 1985; 25:745.

38. Tackett RL, Plunkett LM. Naloxone inhibits the central hypotensive actions of propranolol. The Pharmacologist 1983;25:101.

39. Plunkett LM, Vallner JJ, Tackett RL. Prazosin lowers plasma digoxin levels. American Heart Assoc, pp 15, Savannah, GA, 1983.

40. Tackett RL, Plunkett LM. 1983. BHT 933 lowers blood pressure and increases cerebrospinal fluid norepinephrine levels. American Heart Assoc, pp 16, Savannah GA, 1983.

41. Bayoumi SM, Gokhale R, Plunkett L, Vallner JJ. Pharmacokinetics of clortrimazole in dogs. Acad. Pharmaceut. Sci 1983;13(2):204, (Miami meeting).

42. Plunkett LM, Tackett RL. Central alpha receptors and their role in digitalis cardiotoxicity. The Pharmacologist 1982; 24:489A.43. Plunkett LM, Tackett RL. Central alpha antagonism decreases blood pressure in the dog. Proc. Soc. Exp. Biol. Med. S.E. Sec. 7:12A 1982.

1. Plunkett LM. Regulatory primer for pharmacy students: focus on human therapeutics. Invited speaker for the AAPS Visiting Scientist Program, Texas A&M University, College of Pharmacy, Kingsville, TX, May 1, 2009.

2. Plunkett, LM. Strategies for reducing adverse drug reactions: Science versus regulatory considerations. Invited speaker for the AAPS Visiting Scientist Program, Texas A&M University, College of Pharmacy, Kingsville, TX, May 1, 2009.3 Plunkett L.M. Novelty requirement of §102. Lecturer at Drexel University School of Law. September 22 and 24, 2008.

4. Plunkett L.M. Novelty requirement of §102. Lecturer at Rutgers School of Law, Camden Campus. September 22 and 24, 2008.

5. Plunkett L.M. Discussion of the Adequacy of Current Regulatory Risk Assessment Approaches for Protection of Children’s Health and the Health of Other "Sensitive" Human Subpopulations. Testimony before the U.S. Senate Enviornment and Public Works Committee. April, 29, 2008.

6. Plunkett LM. Strategies for reducing adverse drug reactions: Science versus regulatory considerations. Invited speaker for the AAPS Visiting Scientist Program, Florida A&M University, Tallahassee, FL, October 26, 2006.

7. Plunkett LM. The guidance as currently implemented: experience with Minnesota’s draft risk levels. Presented at the ISRTP workshop entitled: EPA’s New (Proposed) Guidance for Assessing Cancer Risks from Early Life Exposures. Genotoxic Mode of Action and Implications for Human Health-Based Standards. Baltimore, MD February 10, 2005.

8. Plunkett LM. An overview of the regulation of products of biotechnology: Who’s in charge? Lecturer at University of Houston at Clearlake, November 17, 2004.

9. Plunkett LM. Moderator of the symposium entitled "Regulation of genetically modified cells, foods, organisms and animals for consumer and therapeutic use. Meeting of the American Association of Pharmaceutical Sciences (AAPS), Baltimore, MD, November 11, 2004.

10. Plunkett LM. A Road map to the US Food And Drug Administration Regulations. Invited Speaker and Session Co-chair, Federation of European Biochemical Societies (FEBS), Istanbul, Turkey, October 20-24, 2002.

11. Plunkett LM. An overview of the regulation of products of biotechnology: Who’s in charge? Lecturer at University of Houston at Clearlake, November 2001.

12. Plunkett LM . Differences and Similarities Between Children and Adults in their Exposure and Response to Environmental Chemicals: An Update Since 1992. Invited Speaker at ToxForum, Aspen CO, July 2001.

13. Plunkett LM. Do current FIFRA guideline tests protect infants and children? Lead as a case study. Invited speaker at the Sixteenth International Neurotoxicology Conference, Pesticides and Susceptible Populations: Who is at Risk and When? Little Rock, Arkansas, September 13-16 1998

14. Plunkett LM. An overview of biotechnology regulations: the USFDA and the USEPA. Lecturer at University of Houston at Clearlake, October 16 1998.

15. Rodricks JV, Santamaria AB, Plunkett LM. Risk Assessment as a Tool in Litigation: A Discussion of the Uses and Their Limits [Presented by Plunkett LM]. Society for Risk Analysis, , New Orleans, LA. December 10 1996.

16. Plunkett LM. Current Issues in Lead Exposure and Risk Assessment. Symposia at the annual meeting of The American College of Toxicology, Valley Forge, PA. November 9 1996.

17. Plunkett LM . An Overview of Biotechnology Regulations: Environmental Regulations. Lecturer at the South Texas School of Law, October 1995.

18. Plunkett LM. An Overview of Biotechnology Regulations: FDA Regulations. Lecturer at the South Texas School of Law, October 1995.

19. Plunkett LM . A Discussion of Toxicokinetics. Featured speaker at a symposium at the Int. Congress of Toxicol., July 5 1995.

20. Plunkett LM. Chutes and Ladders: The Hazardous Journey for R&D to Market. Featured speaker at the Futurist's Conference, Irvine, CA, June 28, 1995.

1. Plunkett, L.M., Timmerman, L.E. In press. Pharmacovigilance and Postmarket Surveillance in the United States: The Role of the U.S. Food and Drug Administration. In: Elements of Pharmacovigilance: Be Vigilant, Be Safe. R. Sehgal et al. (Eds.), Kongposh Publications: New Dehli.

2. Rodricks JV, Frankos VH, Plunkett LM. 1995. Food Additives. In: Regulatory Toxicology. C.P. Chengelis, J.F. Holson and S.C. Gad (eds.) Raven Press, New York, New York, 51-82.

3. Plunkett LM, Turnbull D, Rodricks JV. 1992. Differences between adults and children affecting exposure assessment. In: Similarities and Differences Between Children and Adults: Implications for Risk Assessment. P.S. Guzelian, C.J. Henry and S.S. Olin (eds.) ILSI Press, Washington D.C., 79-96.

4. Saavedra JM, Plunkett LM, Correa FMA, Israel A, Kurihara M, Shigematsu K. 1986. Quantitative autoradiography of angiotensin and atrial natriuretic factor binding sites in brain nuclei of spontaneously hypertensive rats. In Brain Peptides and Catecholamines in Cardiovascular Regulation in Normal and Disease States.　

1. Plunkett LM. 2008. U.S. Senate Committee on Environment & Public Works. Oral testimony. Full Committee hearing entitled "Oversight on EPA Toxic Chemical Policies". Tuesday, April 29, 2008.

2. Plunkett LM, Brett SM. 1991. A new look at lead: sources, exposures, and uptake in populations at risk. ENVIRON Report. 5:6-9.

3. Plunkett LM, Frankos VH. 1991. FDA re-examines the safety of silicone gel-filled breast implants. ENVIRON Report. 5:10-13.BOOK CHAPTERS